Stay updated with breaking news from Zyme Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chemotherapy pro-drug harnessing proprietary pre|CISION linker technology designed to address safety limitations associated with standard-of-care doxorubicin Phase I dose-escalation and expansion
Project supports Croda's global Research Development Digital Program across all R&D locations Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of
ERS Genomics Limited: ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement License agreement to enhance Nippon Gene's CRISPR/Cas9 research reagents offering ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfol...
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that it has received notice
Arguments filed in opposition to JP6692856 rejected JP2019-210828 represents third Japanese patent ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9